Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) EBT (2021 - 2025)

Historic EBT for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to -$52.8 million.

  • Prime Medicine's EBT fell 59.79% to -$52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$199.6 million, marking a year-over-year increase of 896.7%. This contributed to the annual value of -$195.9 million for FY2024, which is 127.51% up from last year.
  • Per Prime Medicine's latest filing, its EBT stood at -$52.8 million for Q3 2025, which was down 59.79% from -$52.6 million recorded in Q2 2025.
  • Prime Medicine's EBT's 5-year high stood at -$18.8 million during Q3 2021, with a 5-year trough of -$65.6 million in Q4 2023.
  • Over the past 5 years, Prime Medicine's median EBT value was -$45.6 million (recorded in 2024), while the average stood at -$44.4 million.
  • In the last 5 years, Prime Medicine's EBT skyrocketed by 3585.41% in 2022 and then tumbled by 7439.77% in 2023.
  • Prime Medicine's EBT (Quarter) stood at -$61.5 million in 2021, then surged by 35.85% to -$39.5 million in 2022, then plummeted by 66.32% to -$65.6 million in 2023, then surged by 35.6% to -$42.3 million in 2024, then fell by 24.97% to -$52.8 million in 2025.
  • Its EBT stands at -$52.8 million for Q3 2025, versus -$52.6 million for Q2 2025 and -$51.9 million for Q1 2025.